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OBJECTIVE— Impaired lung function and innate immunity have both attracted growing
interest as a potentially novel risk factor for glucose intolerance, insulin resistance, and type 2
diabetes. We aimed to evaluate whether surfactant protein D (SP-D), a lung-derived innate
immune protein, was behind these associations.
RESEARCH DESIGN ANDMETHODS— Serum SP-D was evaluated in four different
cohorts. The cross-sectional associations between SP-D and metabolic and inflammatory param-
eters were evaluated in two cohorts, the cross-sectional relationship with lung function in one
cohort, and the longitudinal effects of weight loss on fasting and circadian rhythm of serum SP-D
and cortisol concentrations in one prospective cohort.
RESULTS— In the cross-sectional studies, serum SP-D concentration was significantly de-
creased in subjects with obesity and type 2 diabetes (P  0.005) and was negatively associated
with fasting and postload serum glucose. SP-D was also associated with A1C, serum lipids,
insulin sensitivity, inflammatory parameters, and plasma insulinase activity. Smoking subjects
with normal glucose tolerance, but not smoking patients with type 2 diabetes, showed signifi-
cantly higher serum SP-D concentration than nonsmokers. Serum SP-D concentration correlated
positively with end-tidal carbon dioxide tension (r 0.54, P 0.034). In the longitudinal study,
fasting serum SP-D concentration decreased significantly after weight loss (P 0.02). Moreover,
the main components of cortisol and SP-D rhythms became synchronous after weight loss.
CONCLUSIONS— These findings suggest that lung innate immunity, as inferred from
circulating SP-D concentrations, is at the cross-roads of inflammation, obesity, and insulin
resistance.
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Impaired lung function has attractedgrowing interest in association withmetabolic disorders (1–6). Decreased
lung function has been proposed as a po-
tential novel risk factor for glucose intol-
erance, insulin resistance, and type 2
diabetes (1–6). In prospective studies of
middle-aged men and women without
known lung disease, lower vital capacity
predicted the subsequent development of
type 2 diabetes. Lower forced vital capac-
ity and forced expiratory volume in 1 s at
baseline predicted hyperinsulinemia and
estimated insulin resistance over 20 years
of follow-up, independent of age, adipos-
ity, and smoking (1).
Possible mechanisms for the hypoth-
esized link include direct effects of hypox-
emia on glucose and insulin regulation
(7), adverse early-life exposures and their
effects on organ development (8), and
lung-related inflammatory mediators and
their effects on insulin signaling (9). In
fact, nuclear factor interleukin-6, early
growth response-1, and hypoxia-
inducible factor-1 mediate inflammatory
responses to chronic hypoxia in macro-
phages, pulmonary vascular endothe-
lium, and smooth muscle (6,9). Cigarette
smoking, an independent predictor of
type 2 diabetes (10), provokes an inflam-
matory response (11) and is inversely as-
sociated with vital capacity. However, the
link between lower vital capacity and di-
abetes risk was completely independent
of cigarette exposure and was stronger in
never-smokers (6).
Reduced vital capacity is a common
residual effect of lower respiratory tract
infections, including those in childhood
and infancy (8), that might provoke an
inflammatory response. A reduced ability
to sense and eradicate pathogens could
thus cause frequent respiratory tract in-
fections, reduced vital capacity, and
chronic inflammation resulting in insulin
resistance and type 2 diabetes (12). The
total incidence rate of infections needing
hospitalization in diabetic patients was
41/1,000 persons-years compared with
16/1,000 person-years of follow-up in the
general population. Roughly half of the
infections were severe lung infections,
suggesting impaired lung immunity in
patients with type 2 diabetes (13).
Pulmonary surfactant is a complex
mixture of lipids (90%) and proteins (5–
10%) that constitutes the mobile liquid
phase covering the large surface area of
the alveolar epithelium. It maintains min-
imal surface tension within the lungs to
avoid lung collapse during respiration.
The innate immune system, by upregulat-
ing SP-D synthesis, can immediately re-
spond to intrusion of foreign agents by
helping to prevent further invasion (14).
This recognition is important in the day-
to-day physiology. Each day, we breathe
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7,000 liters of air, laden with inorganic
and organic particles and an array of mi-
crobes. Secreted primarily by alveolar ep-
ithelial type II pneumocytes, plasma SP-D
appears to increase early in the clinical
course of lung injury, and its concentra-
tion is thought to reflect pulmonary epi-
thelial injury (15).
Subtle deficiencies in proteins of the
sensing arm of the innate immune system
have been found to be associated with al-
terations of glucose metabolism. These
deficiencies run in parallel with inflam-
mation and impaired insulin action (16).
We hypothesized that SP-D could be
behind the association of lung function
with impaired insulin action. For that rea-
son, we aimed to evaluate SP-D according
to metabolic and inflammatory parame-
ters. As SP-D was associated with obesity
status and impaired glucose metabolism,
we evaluated the influence of weight loss
on both fasting and circadian serum SP-D
concentration. As glucocorticoids seem to
regulate SP-D production in in vitro stud-
ies (17), we investigated the influence of
circadian cortisol rhythm on serum SP-D
concentration. Finally, we also studied
the association of SP-D with lung function
tests.
RESEARCH DESIGN AND
METHODS
Cohort 1: study of circulating SP-D
across categories of glucose
tolerance
A total of 388 Caucasian subjects were
recruited and studied. A total of 308 of
them were recruited in an ongoing study
dealing on nonclassical cardiovascular
risk factors in Northern Spain. Subjects
were randomly localized from a census
and were invited to participate. The par-
ticipation rate was 71%. A 75-g oral glu-
cose tolerance test according to the
American Diabetes Association criteria
was performed in all subjects. All subjects
with normal glucose tolerance (n  204)
had fasting plasma glucose 7.0 mmol/l
and 2-h postload plasma glucose 7.8
mmol/l after a 75-g oral glucose tolerance
test. Glucose intolerance was diagnosed
in 64 subjects according to the American
Diabetes Association criteria (postload
glucose between 7.8 and 11.1 mmol/l).
Previously unknown type 2 diabetes was
diagnosed in 40 of these 308 subjects
(postload glucose 11.1 mmol/l). Inclu-
sion criteria were 1) BMI 40 kg/m2, 2)
absence of systemic disease, and 3) ab-
sence of infection within the previous
month. None of the control subjects were
under medication or had evidence of met-
abolic disease other than obesity. Alcohol
and caffeine were withheld within 12 h of
performing the insulin sensitivity test.
Smokers were defined as any person con-
suming at least one cigarette a day in the
previous 6 months. Resting blood pres-
sure was measured as previously re-
ported. Liver disease and thyroid
dysfunction were specifically excluded by
biochemical workup.
To increase the statistical power of the
group of patients with type 2 diabetes, 80
patients were prospectively recruited
from diabetes outpatient clinics on the ba-
sis of stable metabolic control in the pre-
vious 6 months, as defined by stable A1C
values. Data from these patients were
merged with those from the recently di-
agnosed type 2 diabetic patients.
Study of insulin sensitivity
In those subjects who agreed (n  230),
insulin sensitivity and glucose effective-
ness were measured using the frequently
sampled intravenous glucose tolerance
test with minimal model analysis. In brief,
the experimental protocol started be-
tween 8:00 and 8:30 A.M. after an over-
night fast. A butterfly needle was inserted
into an antecubital vein, and patency was
maintained with a slow saline drip. Basal
blood samples were drawn at 30, 10,
and 5 min, after which glucose (300
mg/kg body wt) was injected over 1 min
starting at time 0, and insulin (Actrapid,
Novo, Denmark; 0.03 units/kg) was ad-
ministered at time 20. Additional samples
were obtained from a contra-lateral ante-
cubital vein up to 180 min.
Cohort 2
Findings in the cross-sectional study were
evaluated again in an independent pro-
spective population-based survey of dia-
betes and cardiovascular risk factors (18).
The baseline examination was carried out
during 1998–1999. Randomly popula-
tion-based selected subjects were evalu-
ated to determine the prevalence of type 2
diabetes and pre-diabetes in northwest-
ern Spain. In 2004 –2005, these same
subjects were invited for a follow-up ex-
amination. Seven hundred subjects par-
ticipated. Circulating SP-D concentration
was evaluated in randomly selected sub-
jects (n  333, 137 men and 196
women). Oral glucose tolerance test was
performed as previously described (18).
Measurements of SP-D were centralized
in a single laboratory, as described below.
Cohort 3: study of the effects of
weight loss on circadian circulating
SP-D
The study group included eight normo-
tensive obese women (BMI 40 kg/m2)
evaluated before and 2 years after bilio-
pancreatic diversion. None of the study
participants had endocrine or nonendo-
crine diseases. They were not taking any
medications, except subjects after bilio-
pancreatic diversion, who were pre-
scribed oral supplementation of sulfate
iron (525 mg daily), calcium carbonate (1
g daily), multivitamins (Supradyn Roche,
Milan, Italy) (one tablet a day), and ergo-
calciferol (400,000 IU intramuscular)
(Ostelin fl, Teofarma, Italy) every 2
weeks. Medical histories, physical exami-
nations, electrocardiogram, and blood
screening showed that patients were in
good health. Insulin sensitivity was esti-
mated by a euglycemic-hyperinsulinemic
clamp as previously described. Whole-
body glucose uptake, normalized by fat-
free mass (FFM) (M value in mmol 
kgFFM
1  min1), was determined dur-
ing a primed constant infusion of insulin
(at the rate of 6 pmol  min–1  kg–1).
To evaluate the intra-day SP-D and
cortisol release pattern, the zero mean
transformed series have been calculated:
vt  xt  xt
where t  09.00, 10.00, …, 08.00. Fi-
nally the averaged patterns, before and af-
ter treatment, of these zero mean profiles
were obtained and, using the Matlab
(TheMathWorks, Inc.) program, were ap-
proximated by means of the finite Fourier
series:
a0 
k1
n
	ak cos k
t  bk sin k
t.
The goodness of fit was determined by
means of the degree of freedom adjusted
coefficient of determination: Radj
2 . A value
of this latter parameter equal to 1 indi-
cates a perfect agreement between the ex-
perimental data and the fitted curve.
The Ethical Committee of Catholic
University approved the study, and sub-
jects signed an informed consent docu-
ment before participation.
Cohort 4: study of the association
between circulating SP-D and lung
function
We explored 15 obese subjects (12
women, 3 men), aged 40.4  14.8 years,
SP-D and insulin sensitivity
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with a mean BMI of 46.4  8.8 kg/m2.
Spirometry was performed with a cali-
brated, dry-rolling seal spirometer
(SensorMedics 2130 System; SensorMed-
ics, Yorba Linda, CA) according to current
guidelines, as previously described (19).
Static lung volumes were measured by
body plethysmography (SensorMedics
V6200 Autobox; SensorMedics). The pre-
dicted values used for spirometric and
thoracic gas volumes were those of the
1993 European update.
Patients underwent ventilatory drive
assessment, including minute ventilation
(VE), tidal volume (VT), inspiratory time
(tI), mouth occlusion pressure at 0.1 s of
inspiration (P0.1), and end-tidal carbon
dioxide tension (PET,CO2).
All subjects gave written informed
consent after the purpose of the study was
explained to them. The institutional re-
view board of the participant institutions
approved the protocol.
Analytical methods
Serum glucose concentrations were mea-
sured in duplicate by the glucose oxidase
method using a Beckman glucose ana-
lyzer II (Beckman Instruments, Brea, CA).
Total serum cholesterol was measured
through the reaction of cholesterol ester-
ase/cholesterol oxidase/peroxidase. Total
serum triglycerides were measured
through the reaction of glycerol-
phosphate-oxidase and peroxidase. A1C
was measured by the high-performance
liquid chromatography method (Bio-Rad,
Muenchen, Germany, and autoanalyzer
Jokoh HS-10). Intra-assay and interassay
coefficients of variation were 4% for all
these tests.
Serum insulin levels were measured
in duplicate by monoclonal immunora-
diometric assay (or enzyme-amplified
sensitivity immunoassay [EASIA], Med-
genix Diagnostics, Fleunes, Belgium). In
the replication study, insulin resistance
was calculated using the HOMA value
[glucose (mmol/l)  insulin (mU/l)/
22.5].
Plasma sTNFR1 and sTNFR2 levels
were analyzed by a commercially avail-
able solid-phase MEDGENIX sTNFR1
and sTNFR2 EASIA (BioSource Europe
S.A., Zoning Industriel B-6220, Fleunes,
Belgium). The intra- and interassay coef-
ficients of variation were 7 and 9%.
Serum lipopolysaccharide-binding
protein (LBP) levels were determined
with a commercially available Human
LBP enzyme-linked immunosorbent as-
say (ELISA) kit (HyCult biotechnology
b.v.; PB Uden, the Netherlands). Intra-
and interassay coefficients of variation
were between 5 and 10%.
ELISA of SP-D
The measurements of SP-D concentra-
tions were centralized in a single labora-
tory and analyzed by a sandwich enzyme
immunoassay (Human SP-D ELISA
RD194059100; BioVendor Laboratory
Medicine, Brno, Czech Republic) accord-
ing to the manufacturer’s instructions.
The assay has a sensitivity of 2.2 ng/ml.
Intra-assay coefficient of variation was
5%, and interassay coefficient of varia-
tion was 10%.
Plasma insulinase activity
In brief, 150l serum was incubated with
750 l Tris buffer 100 mmol/l, 1% BSA.
After 30 at 30°C, 125I-insulin (iodinated
at 14B position, 10,000 cpm) is added
and then incubated at 37°C for 30, 60,
and 90 min. Trichloroacetic acid (10%),
which precipitates intact insulin, is finally
added to this mixture. After centrifuga-
tion at room temperature, the supernatant
is separated. Radioactivity units are mea-
sured in the supernatant and in the pre-
cipitated fraction. As trichloroacetic acid
precipitates only intact insulin, degraded
insulin remains only in the supernatant.
Results are expressed as percent radioac-
tivity found in the supernatant relative to
total activity measured in the tube.
Statistical methods
Descriptive results of continuous vari-
ables are expressed as mean (SD). Before
statistical analysis, normal distribution
and homogeneity of the variances were
evaluated using Levene’s test and then
variables were given a base 10 log-
transformation if necessary. These param-
eters (insulin sensitivity [SI], glucose
effectiveness [SG], triglycerides, LBP, and
SP-D) were analyzed on a log scale and
tested for significance on that scale. The
anti–log-transformed values of the means
(geometric mean) are reported in the ta-
bles found in the online appendix (http://
care.diabetesjournals.org/cgi/content/full/
dc09-0542/DC1). The relation between
variables was tested using Pearson’s test
and stepwise multiple linear regression
analysis. We used the 2 test for compar-
isons of proportions and the unpaired t
tests for comparisons of quantitative vari-
ables. General linear model was also used
to calculate circulating SP-D values after
adjusting for age and BMI. The statistical
analyses were performed using the pro-
gram SPSS (version 12.0).
RESULTS
Cohort 1: circulating SP-D across
categories of glucose tolerance and
smoking status
Circulating SP-D was skewed to the left in
the population studied. Log-transformed
serum SP-D followed a normal curve and
was then used in all the analyses per-
formed. Characteristics of the subjects
and the comparisons with type 2 diabetic
subjects are shown in supplemental Table
1. Subjects with glucose intolerance or
type 2 diabetes were significantly older,
heavier, and showed lower insulin sensi-
tivity and glucose effectiveness than sub-
jects with normal glucose tolerance.
Circulating SP-D was significantly
lower among patients with type 2 diabetes
(supplemental Table 1). After adjustment
for BMI, age, and smoking status, mean
log-transformed serum SP-D was signifi-
cantly lower in patients with type 2 dia-
betes (1.79  0.15 [61.6 ng/ml] vs.
1.91  0.17 in subjects with glucose in-
tolerance (81.2 ng/ml) and 1.88 0.13 in
subjects with normal glucose tolerance
(75.8 ng/ml) (P  0.005).
We also observed an interaction be-
tween smoking and glucose tolerance sta-
tus. Smokers with normal glucose
tolerance showed significantly higher
mean log–SP-D than nonsmokers
(1.92  0.28 vs. 1.84  0.22, P 0.03),
and a trend was observed in subjects with
impaired glucose tolerance (2.00  0.22
vs. 1.88  0.23, P  0.08) but not in
patients with type 2 diabetes (1.78 0.25
vs. 1.79 0.20, P 0.92) (supplemental
Fig. 1).
Serum SP-D concentrations did not
differ between patients with type 2 diabe-
tes treated with statins, fibrates, insulin,
hypoglycemic agents, antihypertensive
agents, or allopurinol versus patients who
did not receive these drugs. However,
those patients receiving aspirin (n  46)
showed a trend toward decreased serum
SP-D concentration (1.74  0.23 vs.
1.81  0.20, P  0.08) despite similar
age (58.3 8.7 vs. 56.5 11.8, P 0.4)
and BMI (29.7  4.1 vs. 28.9  3.7, P
0.3). Obese subjects showed significantly
decreased serum SP-D concentrations
(log SP-D 1.80  0.20 vs. 1.86  0.24,
P  0.03).
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Associations with variables of
glucose metabolism and
inflammation
In all subjects as a whole, circulating SP-D
correlated significantly with serum glu-
cose 30 post–oral glucose tolerance test,
LBP, TNFR2, and insulin sensitivity. In
subjects with altered glucose tolerance,
these associations were strengthened. In
this subgroup, we also observed signifi-
cant associations with A1C, fasting trig-
lycerides, HDL cholesterol, and glucose
effectiveness (supplemental Table 2). The
association between SP-D and insulin
sensitivity was most significant in subjects
with glucose intolerance (r  0.40, P 
0.002; supplemental Fig. 2).
Circulating SP-D run in inverse pro-
portion to serum LBP (patients with type
2 diabetes showed the highest serum LBP
concentration and the lowest serum SP-D
concentration in both smokers and non-
smokers) (supplemental Fig. 3).
We performed a multiple linear re-
gression analysis to predict circulating
SP-D. We considered as independent
variables those with significant associa-
tion on univariate analysis. When all sub-
jects were considered as a whole, only age
(P  0.01) and fasting glucose (P 
0.001) contributed independently to
11% of SP-D variance (4 and 7%, respec-
tively), after controlling for the effects of
age, BMI, smoking status, fasting triglyc-
erides, LBP, and insulin sensitivity. When
the analysis was performed in subjects
with altered glucose tolerance, fasting
glucose (P 0.0001, r2  0.18) and fast-
ing triglycerides (P  0.001, r2  0.15)
contributed independently to 33% of
SP-D variance.
Study of possible mechanisms
To evaluate the possible mechanisms be-
hind the association between SP-D and
glucose metabolism, we studied insuli-
nase activity in a sample of consecutive
subjects whose characteristics did not
differ significantly from the remaining
subjects. We found that serum SP-D
was significantly associated with insuli-
nase activity (P  0.005) (supplemental
Fig. 4).
Cohort 2
SP-D was evaluated in 333 subjects (137
men) without previously known type 2
diabetes, mean age 50.7 7.6 years, BMI
27.6  4.6 kg/m2, in whom plasma sam-
ples were available. These subjects were
significantly younger than the whole co-
hort (P 0.03) but was otherwise similar
in sex, BMI, and fasting glucose values.
Among these subjects, circulating SP-D
was negatively associated with BMI (r 
0.19, P  0.001), systolic blood pres-
sure (r  0.13, P  0.01), and fasting
glucose (r  0.14, P  0.009). The
findings were especially significant
among nonsmoking subjects (n 254) in
whom SP-D was negatively associated
with BMI (r0.14, P 0.02), systolic
blood pressure (r  0.13, P  0.03),
and fasting and postload glucose levels
(r  0.16, P  0.009, and r  0.13,
P  0.04, respectively). Among non-
smoking women (n 157), the most sig-
nificant association was between SP-D
and postload glucose levels (r  0.21,
P 0.008), and among nonsmoking men
(n 97), the most significant association
was between SP-D and systolic blood
pressure (r0.33, P 0.001). Among
current smokers (n  79), only the asso-
ciation of SP-D with BMI persisted signif-
icantly (r  0.27, P  0.015).
Cohort 3
Both fasting and 24-h area under the
curve of serum SP-D concentration de-
creased significantly after weight loss
(from 70.7  34.8 to 31.1  4.3 ng/ml,
P 0.02, and from 1,594 831 to 702
106 ng  ml1  h1, P  0.03, respec-
tively). The change in 24-h area under the
curve of serum SP-D concentration
tended to be associated with the change in
insulin sensitivity (r0.77, P 0.07).
A finite Fourier series with n 8 approx-
imated the experimental SP-D data with
Radj
2  0.75 in basal condition and with
Radj
2  0.81 after weight loss (supple-
mental Fig. 5). Frequency composition
was similar before and after weight loss,
but after surgery, the spectral component
fluctuations had lower amplitude than
before. These results suggest a decrease in
protein fluctuations. The principal spec-
tral component had a period  24
hour
cycle
;
other components, with a lower ampli-
tude, were found at  12
hour
cycle
and
 6
hour
cycle
.
Regarding circadian rhythm of corti-
sol, a five terms Fourier series approxi-
mate the experimental data with Radj
2 
0.98 in the basal condition as well as after
weight loss (supplemental Fig. 5). The
spectral components with higher ampli-
tudes were found at  24
hour
cycle
and
at  12
hour
cycle
. The higher-order harmon-
ics were negligible. However, the compo-
nent at  6
hour
cycle
was more evident than
others (supplemental Fig. 5).
Taking into consideration the rela-
tionships between diurnal variability of
cortisol and SP-D, we have considered the
first, second, and fourth harmonic of the
estimated Fourier series. In fact, these
components are the most representative
for both parameters.
Before weight loss, we observed that
the first harmonic had a similar pattern in
both parameters, with a small time lag for
SP-D (supplemental Fig. 5). In fact, the
first component of SP-D had its maximum
value at the middle of the day. The second
and fourth harmonics showed opposite
phases: cortisol assumed peak values
when SP-D reached a minimum value.
After weight loss, the examined har-
monics of SP-D changed their phases (Fig.
1). Apart from a small time lag, the second
and fourth harmonics were in phase; on
the contrary, the first harmonic of SP-D
showed a phase near opposite that of cor-
tisol. In other words, weight loss induced
a synchronous variability of SP-D and
cortisol components with a period of
 12
hour
cycle
and  6
hour
cycle
.
Cohort 4
We observed no associations between se-
rum SP-D concentration and any of the
parameters of lung function tested, both
before and after weight loss. Serum SP-D
concentration was not significantly asso-
ciated with forced vital capacity, forced
expiratory volume in 1 s, or expiratory
reserve volume. However, serum SP-D
concentration correlated positively with
end-tidal carbon dioxide tension
(PET,CO2) (r  0.54, P  0.034) in all
subjects as a whole.
CONCLUSIONS— The main find-
ings of this study are as follows: 1) serum
SP-D concentration was significantly de-
creased in patients with type 2 diabetes
(age-, BMI- and smoking status-
adjusted). 2) The findings were replicated
in an independent cohort of subjects in
whom circulating SP-D correlated with
several metabolic variables (namely, BMI,
fasting, and postload glucose levels and
SP-D and insulin sensitivity
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blood pressure). 3) Weight loss led to sig-
nificantly decreased serum SP-D concen-
trations and to important changes in their
circadian rhythm. 4) Serum SP-D concen-
tration was not significantly associated
with parameters of lung function.
Weight loss had no effects on ultra-
dian cortisol secretion, whereas the pat-
tern of the spontaneous 24-h secretion of
SP-D was modified: those hours of the day
in which SP-D had a peak before weight
loss were those hours in which a valley of
Figure 1—Comparison of the circadian rhythm (harmonics) of serum SP-D and cortisol concentrations before and after weight loss.
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SP-D concentration after weight loss was
observed (supplemental Fig. 5). More-
over, after weight loss, the components
withaperiodof  12
hour
cycle
and  6
hour
cycle
of cortisol and SP-D became synchronous
(Fig. 1).
The effects of glucocorticoids on SP-D
production have been previously de-
scribed to be regulated at the level of tran-
scription in in vitro studies (17). Cortisol
levels are reduced in morbid obesity, a
clear anabolic condition, and cortisol
rhythm is disrupted. As previously de-
scribed, free cortisol levels increase and
its rhythm returns to be regular after mas-
sive weight loss secondary to malabsorp-
tive bariatric surgery (20). It is likely that
this normalized cortisol rhythm conveys
the normalization of SP-D rhythm
through both a quantitative and a tempo-
ral control of the surfactant protein syn-
thesis. This would also explain why SP-D
levels decreased after weight loss. Further
research is needed in subjects without
morbid obesity.
This is the first study, to our knowl-
edge, in which the pattern of secretion of
a lung innate immune protein and the in
vivo relation between SP-D and cortisol
are studied. The implications of this
change of pattern should be further ex-
plored. In this sense, of note were the par-
allel variations in serum LBP and SP-D in
subjects from cohort 1. The same factor
(lipopolysaccharide) could lead to in-
creased serum LBP and decreased SP-D
concentrations. In a recent study, long-
term exposure to lipopolysaccharide en-
hanced the rate of stimulated exocytosis
and surfactant secretion in alveolar type II
cells (21). In fact, lipopolysaccharide is
extraordinarily ubiquitous in nature, be-
ing present in food and water, in normal
indoor environments as a constituent of
house dust, and of cigarette smoke. Both
smoking as inflammatory stimulus, and
plasma TNFR2 concentration, were posi-
tively associated with serum SP-D
concentrations.
Interestingly, smoking led to signifi-
cantly increased serum SP-D concentra-
tions among subjects with normal glucose
tolerance, but this was not observed in
subjects with glucose intolerance or type
2 diabetes. This finding suggests that nor-
mal insulin action is needed to increase
serum SP-D after an inflammatory stimu-
lus. In fact, insulin receptors are present
in rabbit type II pneumocytes (precisely
those that produce SP-D) and insulin led
to increased surfactant synthesis in in
vitro studies (22). Glucagon-like peptide
1, known to stimulate insulin secretion,
also stimulated surfactant secretion in hu-
man type II pneumocytes.
The associations between SP-D and
BMI have been recently reported (23). We
evaluated a possible mechanism of the as-
sociation between SP-D and glucose me-
tabo l i sm. We found a nega t ive
relationship between plasma insulinase
activity and serum SP-D (Fig. 4). We took
advantage of a recent article showing that
SP-D is inactivated by neutrophil serine
proteinases (24). Insulinase activity has
been shown to be increased 14.5-fold in
neutrophils from diabetic patients. A
number of different peptides have been
described to be degraded by insulinase,
including insulin, IGF-I, and IGF-II. It is
unknown whether SP-D could be cleav-
aged by insulinase. However, a third fac-
tor leading to increased insulinase activity
and decreased SP-D seems more plausi-
ble. In fact, some molecules with insuli-
nase activity (protein disulfide isomerase)
seem to control simultaneously insulin
degradation and the inflammatory
process.
Finally, we did not find any signifi-
cant relationship between serum SP-D
concentration and lung function tests.
Obese subjects have respiratory impair-
ment due to the increment of total body
fat, which produces diminished compli-
ance and increased resistance and work of
breathing. Most obese subjects have an
increased respiratory drive and a dimin-
ished hypercapnic response (19). These
alterations are explained mainly by me-
chanical factors, as the extra fat load pro-
vokes higher work of breathing (19). We
observed that serum SP-D concentration
correlated positively with end-tidal car-
bon dioxide tension (PET,CO2), but the
meaning of this association remains to be
explored more in-depth. In fact, the li-
poprotein complex surfactant is essential
for reducing surface tension at the air–
liquid interface of the lung and for lung
immune host defense. Relatively little is
known about the in vivo role of this pro-
tein in chronic lung diseases. Because
there was no correlation of SP-D with vital
capacity, this finding cannot explain why
subjects with lower lung capacity are at a
higher risk of diabetes.
Fasting glucose and fasting triglycer-
ides contributed significantly to the vari-
ance of circulating SP-D concentrations.
Glucose is a known ligand for SP-D. Neu-
tralization of different viruses by SP-D is
abolished in the presence of increased
glucose levels in mice. A number of respi-
ratory illnesses to which diabetic patients
show particular susceptibility are known
to be agglutinated by SP-D (25). We spec-
ulate that repeated viral infection in pa-
tients with reduced SP-D levels could lead
to inflammation and worsening of carbo-
hydrate metabolism. However, the re-
verse hypothesis cannot be excluded:
SP-D might be regulated by glucose, trig-
lycerides, and inflammation.
In summary, the findings of the
present study suggest that lung innate im-
munity, as inferred from circulating SP-D
concentrations, could be at the crossroads
of inflammation, obesity, and insulin re-
sistance. Circulating SP-D levels should
be evaluated in future studies to explore
whether their concentrations predict the
development of type 2 diabetes or de-
crease after the impairment of carbohy-
drate metabolism. The measurement of
SP-D bioactivity in vivo and SP-D levels in
bronchoalveolar lavage will be necessary
to evaluate the underlying mechanisms
connecting obesity, insulin resistance, in-
flammation, and SP-D.
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